G

Gilead Sciences

Makes medicines for HIV, liver disease and cancer

Associate Director - IT Data and AI

Full-TimeUpdated on 10/16/2026
$169k - $218.7k+ Discretionary annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's
Raleigh, NC, USA
Hybrid
Engineering ManagementEngineering Leadership
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A bachelor's degree with 10+ years of relevant experience, or a master's degree with 8+ years of relevant experience.
  • Experience leading AI/ML delivery programs in Agile environments.
  • Hands-on experience in data engineering, data science, or architecture.
  • Strong understanding of AI/ML architectures and cloud platforms.
  • Strong leadership, communication, and stakeholder management skills.
  • A product-centric mindset with a focus on value realization.
Responsibilities
  • Drive end-to-end technical delivery of AI/ML solutions supporting clinical operations, data management, safety, and regulatory domains, ensuring scalable, high-quality delivery.
  • Make hands-on architecture decisions, establish code quality standards, and apply advanced analytics methodologies to deliver measurable impact from concept through scaled release.
  • Own end-to-end delivery, including timelines and technical quality, of Clinical Development AI use-case solutions from ideation through production.
  • Apply a product-centric approach with clear ownership, roadmaps, and user adoption metrics.
  • Manage Agile delivery, including sprint planning, backlog prioritization, and releases.
  • Oversee development of scalable solutions using Databricks, AWS, and enterprise Data & AI platforms.
  • Lead hybrid technical delivery teams, drawing on technical experts within and beyond the team.
  • Facilitate technical problem solving across clinical development domains.
  • Shape technical standards for research data models, storage, and automation workflows.
  • Maintain technical documentation and runbooks for Clinical Development data pipelines and agents, and serve as the escalation point for technical risks and delivery blockers.
  • Ensure integration with enterprise data platforms and reusable components.
  • Define and enforce technical standards for AI/ML and data pipelines.
  • Monitor product performance and drive continuous improvement toward quantifiable targets; track delivery, performance, and adoption metrics.
  • Manage vendor relationships and co-sourced delivery teams.
  • Ensure compliance with data governance, security, and regulatory requirements, including GxP.
Desired Qualifications
  • Experience in clinical development, including trial operations, data management, or safety.
  • Experience in clinical AI/ML use cases.
  • Experience in GxP-regulated environments.
  • Exposure to generative AI applications.
  • Familiarity with clinical systems such as EDC and regulatory platforms.

About the company

Gilead Sciences is a biopharmaceutical company that discovers, develops and sells medicines for HIV, viral hepatitis and other liver diseases, cancer and inflammatory conditions. Its HIV business covers both treatment, led by the once-daily pill Biktarvy, and prevention, including Descovy and Yeztugo, a lenacapavir injection given twice a year. In cancer, its Kite unit makes CAR T-cell therapies from patients' own immune cells, and Trodelvy is an antibody-drug conjugate for breast cancer. Gilead earns revenue by selling its drugs to wholesalers, specialty pharmacies, hospitals and governments worldwide after regulatory approval. The company was founded in 1987 and is headquartered in Foster City, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead is expanding at headquarters: it broke ground on a Foster City biologics plant in August 2026.
  • Its top seller has a long runway: generic deals keep US copies of Biktarvy off shelves until April 2036.
  • Acquisitions add teams to join: Gilead bought German drug developer Tubulis for about $3.2 billion in May 2026.

What critics are saying

  • Sales lean on one disease: HIV drugs made $5.7 billion of Gilead's $7.8 billion revenue in Q2 2026.
  • Medicare will set Biktarvy's price: officials picked it in January 2026 for negotiated prices starting in 2028.
  • Expect cuts: Gilead reported 108 Redwood City and 51 San Mateo layoffs taking effect by June 2026.

What makes Gilead Sciences unique

  • Gilead sells a twice-a-year HIV prevention shot: Yeztugo replaces daily pills with two injections a year.
  • Gilead now fully owns a myeloma cell therapy: it bought partner Arcellx for about $7.8 billion in April 2026.
  • Gilead makes cell therapies in-house: Kite runs its own CAR T plants in California, Maryland and Amsterdam.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Paid family time off and paid parental time off
  • Generous 401(k) contribution matching
  • Comprehensive medical plans that cover both physical and mental healthcare
  • Global Wellbeing Reimbursement
  • Time Off
  • Global Volunteer Day
  • Giving Together Program
  • Employee Support Programs
  • Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
MarketScreener
Oct 14th, 2026
Vir Biotechnology shares jump on Gilead cancer collaboration.

Vir Biotechnology shares jump on Gilead cancer collaboration. Published on 10/14/2026 at 10:00 am EDT - Modified on 10/14/2026 at 10:01 am EDT By Adriano Marchese Vir Biotechnology shares jumped Wednesday morning after the company said it signed an agreement with Gilead Sciences to discover and develop next-generation t-cell engagers for solid tumors. Shares traded 8.2% at $11.48 ahead of the morning bell. The clinical-stage biopharmaceutical company has signed a collaboration and license agreement with Gilead to discover and engineer three novel dual-masked T-cell engager development candidates aimed at targeting solid tumor-associated antigens. T-cell engagers, or TCEs, are powerful anti-tumor agents designed to direct the immune system, specifically T-cells, to destroy cancer cells. TCEs have become an important treatment option for blood cancers, but their usage in solid tumors has been limited due to toxicity. Gilead will have an exclusive license to nominate and advance candidates developed under the collaboration and will be responsible for development, manufacturing and commercialization activities. As part of the deal, Vir will be in line to receive a total of $135 million in payments, made up of a $65 million cash portion and a $25 million equity investment at a 30% premium, as well as up to $45 million in potential near-term preclinical milestones. Vir added that it has the potential to receive up to $1.74 billion in further development, regulatory and commercial milestones, along with tiered high single-digit to low double-digit royalties on net sales. Write to Adriano Marchese at [email protected] (END) Dow Jones Newswires 10-14-26 0959ET (C) Dow Jones - 2026

MarketScreener
Oct 14th, 2026
Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal.

Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal. Published on 10/14/2026 at 09:22 am EDT or by email Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%). Mean consensus Number of Analysts Last Close Price 147.92 USD Average target price 159.62 USD Spread / Average Target

Hip-Hop Wired
Oct 8th, 2026
Raheem DeVaughn on R&B and Black mental health.

Raheem DeVaughn on R&B and Black mental health. Published on October 8, 2026 Raheem DeVaughn talks ownership, R&B, and healing on The Morning Hustle. R&B mainstay Raheem DeVaughn stopped by The Morning Hustle for a conversation that spanned business, music, and community. The DMV favorite opened up about his new project, Quiet Storm Lover Tome Un, and his decision to re-record his 20th-anniversary album, The Love Experience. For DeVaughn, the move is about ownership. Re-recording old work creates a new master, and he wants to lead by example for independent and legacy artists chasing control of their catalogs. He also shared his love for where R&B stands today, praising fresh work from Erykah Badu and Jill Scott. DeVaughn makes music with intention, refusing to chase trends for quick money. "Music is only old to someone who hasn't heard it yet," he said, describing his focus on timeless songs that keep fans dancing for hours at deep-catalog shows. Beyond the mic, DeVaughn stays active in the community. Through his Love Life Foundation and a partnership with Gilead Sciences on the "Care for the Culture" initiative, he urges people to get tested and know their status. He also spoke candidly about mental health, encouraging Black men to seek therapy. Losing his father, he shared, pushed him into the work that revealed his own strength. Looking ahead, DeVaughn teased a City Winery tour bringing his classics to life live for fans. Stories from our partners. OkayAfrica

Boston Cambridge Biotech Networks
Sep 24th, 2026
STAT+: Why Gilead can't stop talking about its ambitions in immunology.

STAT+: Why Gilead can't stop talking about its ambitions in immunology. Speaking at recent investor conferences, Gilead Sciences' top executives have been emphatically bullish about the biotech's years-long push to develop drugs for inflammatory and autoimmune diseases. "It's one of the three scientific areas that are our core focus," Gilead Chief Financial Officer Andy Dickinson told investors at the Cantor Global Healthcare Conference earlier this month. "We're the largest virology company. We've built a robust oncology business. The third leg of the stool, so to speak, is the I&I [inflammation and immunology] business that we're growing."

Yahoo Finance
Sep 15th, 2026
Gilead partners with PAHO to expand twice-yearly lenacapavir HIV prevention access across Latin America

Gilead Sciences has partnered with the Pan American Health Organization (PAHO) to expand access to twice-yearly lenacapavir for HIV prevention across Latin America and the Caribbean. The agreement uses PAHO's Regional Revolving Funds to create a coordinated pathway for country-led adoption of the long-acting HIV prevention treatment. The partnership addresses a critical need in the region, where new HIV infections increased by 13% between 2010 and 2024. The agreement provides access for 14 countries outside Gilead's existing voluntary licensing agreements, including Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Mexico, Panama, Paraguay, Peru, Uruguay and Venezuela. The collaboration combines PAHO's regional coordination and procurement capabilities with Gilead's access strategy to enable sustainable scale-up of HIV prevention efforts.